ScholarLens Back to search
2008•Medical RecapitulateRequires access

Clinical Study on Lamivudine Combined with Thymosin α_1 in the Treatment of Chronic Hepatitis B

Qin Hon

Open publisher page 0 citations

Abstract

Objective To evaluate the clinical efficacy of lamivudine combined with thymosin α1.Method 60 chronic hepatitis B patients were enrolled and randomized into the therapy group and the control group.30 cases in therapy group received lamivudine and thymosin α1 for 6 months,then lamivudine simultaneously for 6 months,30 cases in the control group received lamivudine alone for 12 months.during the treatment blood routine examination,ALT,AST,HBeAg,Anti-HBe and HBV DNA were termly checked and measured.Results All 60 patients completed the study.The seroconversion rates for HBeAg/Anti-HBe and the rates for HBV DNA to change to be negative in combination group were higher than those in control group.Conclusion The efficacy of combination therapy appeared to be better than lamivudine group.

About this research paper

What this paper is about

Objective To evaluate the clinical efficacy of lamivudine combined with thymosin α1.Method 60 chronic hepatitis B patients were enrolled and randomized into the therapy group and the control group.30 cases in therapy group received lamivudine and thymosin α1 for 6 months,then lamivudine simultaneously for 6 months,30 cases in the control group received lamivudine alone for 12 months.during the treatment blood routine examination,ALT,AST,HBeAg,Anti-HBe and HBV DNA were termly checked and measured.Results All 60 patients completed the study.The seroconversion rates for HBeAg/Anti-HBe and the rates for HBV DNA to change to be negative in combination group were higher than those in control group.Conclusion The efficacy of combination therapy appeared to be better than lamivudine group.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To evaluate the clinical efficacy of lamivudine combined with thymosin α1.Method 60 chronic hepatitis B patients were enrolled and randomized into the therapy group and the control group.30 cases in therapy group received lamivudine and thymosin α1 for 6 months,then lamivudine simultaneously for 6 months,30 cases in the control group received lamivudine alone for 12 months.during the treatment blood routine examination,ALT,AST,HBeAg,Anti-HBe and HBV DNA were termly checked and measured.Results All 60 patients completed the study.The seroconversion rates for HBeAg/Anti-HBe and the rates for HBV DNA to change to be negative in combination group were higher than those in control group.Conclusion The efficacy of combination therapy appeared to be better than lamivudine group.

Key concepts: Lamivudine, Medicine, Seroconversion, Internal medicine, Thymosin, Gastroenterology, Chronic hepatitis, HBeAg

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Study on Lamivudine Combined with Thymosin α_1 in the Treatment of Chronic Hepatitis B — Research Paper | ScholarLens